The upcoming case on the "on-sale" bar involving The Medicines Company and Angiomax
From within a post at Statnews on the Angiomax case:
Meanwhile, in its own court filing in support of The Medicines Company, the BIO industry trade group wrote the panel decision “would apply to any contract in which a patent holder uses a CMO [contract manufacturer organization] to assist in producing a product made by a patentable process. Such an interpretation of the on-sale bar discourages use of CMOs and, accordingly, promotes an inefficient and costly method of production of valuable pharmaceuticals.”
link: https://www.statnews.com/pharmalot/2016/05/05/appeals-court-patent-drug-makers/
A prior post on IPBiz:
http://ipbiz.blogspot.com/2015/11/re-hearing-en-banc-granted-to-medicines.html
Meanwhile, in its own court filing in support of The Medicines Company, the BIO industry trade group wrote the panel decision “would apply to any contract in which a patent holder uses a CMO [contract manufacturer organization] to assist in producing a product made by a patentable process. Such an interpretation of the on-sale bar discourages use of CMOs and, accordingly, promotes an inefficient and costly method of production of valuable pharmaceuticals.”
link: https://www.statnews.com/pharmalot/2016/05/05/appeals-court-patent-drug-makers/
A prior post on IPBiz:
http://ipbiz.blogspot.com/2015/11/re-hearing-en-banc-granted-to-medicines.html
posted by Lawrence B. Ebert at 10:00 AM
0 Comments:
Post a Comment
<< Home